Chief Executive Officer

Bryan Mazlish

Bryan Mazlish co-founded Surf Bio in 2021 to commercialize a novel drug stabilization technology. He has been in the life sciences industry for over a decade, since a family diagnosis led him to develop novel insulin delivery systems for the treatment of diabetes. This work led to his co-founding Bigfoot Biomedical in 2014, a medical device company focused on more scalable diabetes therapies leveraging algorithms and AI. In 2021, FDA cleared Bigfoot’s first product, Bigfoot Unity. Bryan presently serves as a Board Member of Bigfoot after leaving his role as President in 2020. Prior to making the transition to life sciences, Bryan led a successful career in quantitative finance, first as management at Citi, and subsequently as an entrepreneur, where he founded and led a fully automated trading company, Overlook Capital. Bryan graduated magna cum laude from Harvard College.

President & Chief Medical Officer

Jennifer Schneider, MD

Jennifer Schneider, MD, is a Stanford trained physician and translational medicine entrepreneur. She is co-founder, President and Chief Medical Officer of Surf Bio. Previously she was founder and CEO of Mode AGC, an insulin dosing algorithm company. Under her leadership, Mode AGC realized a successful exit to Insulet Corporation. Jennifer serves as a strategic advisor and on several boards. She is a member of the International Board of Directors for JDRF and on their Research Committee. She serves on the Clinical Advisory Panel for CIRM (California Institute for Regenerative Medicine), and is a visiting scholar at Stanford. Prior to her work in the diabetes space, Jennifer practiced orthopedic and hand surgery for 15 years at the Palo Alto Medical Foundation and Stanford. She earned her undergraduate degree from Harvard, her MD from Georgetown, and completed her surgical training at Stanford.

Chief Scientific Advisor

Eric Appel, PhD

Eric A. Appel is a professor of material science and bioengineering at Stanford University and serves as Chief Scientific Advisor for Surf Bio. He received his PhD in Chemistry at the University of Cambridge and was awarded the Jon Weaver PhD prize from the Royal Society of Chemistry. Upon graduating from Cambridge, he was awarded a Wellcome Trust Fellowship to work with Prof. Robert Langer at MIT. Eric’s research at Stanford focuses on the development of biomaterials technologies that can be used as tools to better understand fundamental biological processes and to engineer advanced healthcare solutions. Eric also adapted his lab’s approach to develop controlled delivery technologies for wildland fire retardants to enable novel approaches to proactive wildfire prevention. In 2018, Eric founded LaderaTECH to commercialize this technology, which was acquired by Perimeter Solutions in May 2020.